Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells take aim at Hard-to-Treat cancers

NCT ID NCT02830724

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 28 times

Summary

This study tests a new treatment for several types of cancer that have a specific marker called CD70. Researchers take a patient's own white blood cells, modify their genes in the lab to help them recognize and attack CD70-positive cancer cells, and then return them to the patient. The goal is to see if this gene therapy can safely shrink tumors. The study is for adults with advanced pancreatic, kidney, breast, melanoma, or ovarian cancer that has not responded to standard treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.